Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 8NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Leukemia, Myeloid, Acute 5Glioblastoma 4Breast Neoplasms 4Melanoma 3Pathologic Complete Response 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Glioma 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Ovarian Cancer 1Advanced Cancer 1

Interventions

Temozolomide 7Bevacizumab 4sargramostim 2rindopepimut 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 21-methyltryptophan 2ridaforolimus 1prinomastat 1pembrolizumab 1pamiparib 1marizomib 1interferon gamma-1b 1enzastaurin 1depatuxizumab mafodotin 1capmatinib 1Sucrose 1Spermine Synthase 1Radiosurgery 1Procarbazine 1ONC206 1NVP-BKM120 1Leflunomide 1Interferon-gamma 1Interferon-beta 1Immunotherapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gliosarcoma × sargramostim × Clear all
NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed
745 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡